AU2023220646A1 - Methods of treating prostate cancer - Google Patents
Methods of treating prostate cancer Download PDFInfo
- Publication number
- AU2023220646A1 AU2023220646A1 AU2023220646A AU2023220646A AU2023220646A1 AU 2023220646 A1 AU2023220646 A1 AU 2023220646A1 AU 2023220646 A AU2023220646 A AU 2023220646A AU 2023220646 A AU2023220646 A AU 2023220646A AU 2023220646 A1 AU2023220646 A1 AU 2023220646A1
- Authority
- AU
- Australia
- Prior art keywords
- olaparib
- subject
- use according
- abiraterone acetate
- daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263268026P | 2022-02-15 | 2022-02-15 | |
| US63/268,026 | 2022-02-15 | ||
| PCT/EP2023/053555 WO2023156357A1 (en) | 2022-02-15 | 2023-02-14 | Methods of treating prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023220646A1 true AU2023220646A1 (en) | 2024-09-19 |
Family
ID=85283519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023220646A Pending AU2023220646A1 (en) | 2022-02-15 | 2023-02-14 | Methods of treating prostate cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250134887A1 (https=) |
| EP (1) | EP4479053A1 (https=) |
| JP (1) | JP2025505041A (https=) |
| KR (1) | KR20240148418A (https=) |
| CN (1) | CN118829430A (https=) |
| AU (1) | AU2023220646A1 (https=) |
| CA (1) | CA3250763A1 (https=) |
| IL (1) | IL314798A (https=) |
| MX (1) | MX2024009923A (https=) |
| TW (1) | TW202400267A (https=) |
| WO (1) | WO2023156357A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
-
2023
- 2023-02-14 CN CN202380021612.6A patent/CN118829430A/zh active Pending
- 2023-02-14 US US18/837,956 patent/US20250134887A1/en active Pending
- 2023-02-14 EP EP23705969.6A patent/EP4479053A1/en active Pending
- 2023-02-14 WO PCT/EP2023/053555 patent/WO2023156357A1/en not_active Ceased
- 2023-02-14 IL IL314798A patent/IL314798A/en unknown
- 2023-02-14 MX MX2024009923A patent/MX2024009923A/es unknown
- 2023-02-14 JP JP2024547679A patent/JP2025505041A/ja not_active Withdrawn
- 2023-02-14 AU AU2023220646A patent/AU2023220646A1/en active Pending
- 2023-02-14 CA CA3250763A patent/CA3250763A1/en active Pending
- 2023-02-14 KR KR1020247030614A patent/KR20240148418A/ko not_active Withdrawn
- 2023-02-15 TW TW112105268A patent/TW202400267A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250134887A1 (en) | 2025-05-01 |
| EP4479053A1 (en) | 2024-12-25 |
| WO2023156357A1 (en) | 2023-08-24 |
| TW202400267A (zh) | 2024-01-01 |
| KR20240148418A (ko) | 2024-10-11 |
| CN118829430A (zh) | 2024-10-22 |
| MX2024009923A (es) | 2024-08-22 |
| JP2025505041A (ja) | 2025-02-19 |
| IL314798A (en) | 2024-10-01 |
| CA3250763A1 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6857210B2 (ja) | リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法 | |
| Patnaik et al. | First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas | |
| EP3609497B1 (en) | Niraparib, abiraterone acetate and prednisone for treating prostate cancer | |
| US20250235451A1 (en) | Methods of Delaying Pain Progression And Treating Prostate Cancer | |
| EP4618990A1 (en) | Methods of treatment of breast cancer with selective estrogen receptor degraders (serds) | |
| US20250134887A1 (en) | Methods of treating prostate cancer | |
| WO2023175477A1 (en) | Treatment of breast cancer with amcenestrant | |
| JP2025508399A (ja) | 脳がんの処置のためのニラパリブの使用 | |
| RU2808427C2 (ru) | Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан | |
| HK40064914A (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
| WO2022192796A1 (en) | Compositions and methods for treating and/or preventing therapy-related cardiomyopathy associated with neutrophil infiltration | |
| HK40092155A (en) | Combination therapy for prostate cancer | |
| HK40010824A (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
| HK1209627B (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |